Objectives Randomized controlled trials have demonstrated that afatinib is a suitable
treatment option for patients with epidermal growth factor receptor mutation-positive …

Objectives Three epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs)–
afatinib, erlotinib, and gefitinib–are available for the treatment of patients with EGFR …

Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings
from three prospective trials of af Page 1 Activity of afatinib in uncommon epidermal growth …

The development of first-, second-, and third-generation epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non …

Gefitinib, erlotinib and afatinib are approved for first‐line treatment of advanced non‐small
cell lung cancer (NSCLC) bearing an activating epidermal growth factor receptor (EGFR) …

Afatinib, the world's first irreversible ErbB family (containing four different cancer cell
epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a …

Purpose In the randomized phase IIb LUX-Lung 7 trial, afatinib significantly improved
progression-free survival (PFS) and time-to-treatment failure vs gefitinib in patients with …

Background Most patients with non-small-cell lung cancer tumours that have EGFR
mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21 …

Objectives Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are
used as first-line standard treatment for advanced lung adenocarcinoma with mutant EGFR …

Background Afatinib 40 mg/day is approved for first-line treatment of EGFR mutation-positive
non-small-cell lung cancer (NSCLC). In the case of drug-related grade≥ 3 or selected …